

The Govt. of EG, US Energy Companies & Sanaria collaborate for malaria vaccine

11 April 2019 | News

The collaboration is to extend support for clinical development of PfSPZ vaccine for malaria and a pathway towards malaria elimination on Bioko Island



Sanaria Inc. and the Government of Equatorial Guinea last week signed an agreement that continues their joint commitment to develop Sanaria® PfSPZ Vaccine as a tool for malaria elimination. This follows a new, broader agreement between the Government of Equatorial Guinea (EG) and industry partners, Marathon Oil Corporation, Noble Energy Inc. and Atlantic Methanol Production Company (AMPCO), to sponsor clinical development of Sanaria® PfSPZ Vaccine, including the Phase 3 clinical program starting in 2020.

This long standing, successful partnership highlights the unique involvement of an African government and private-sector energy companies in developing a vaccine for a largely African problem. The larger funding program, the Bioko Island Malaria Elimination Program (BIMEP), is targeting elimination of malaria from a population of over 280,000 on Bioko Island by integrating PfSPZ Vaccine into standard anti-malaria activities, including mosquito control and malaria diagnosis and treatment, coordinated by Medical Care Development International.

Malaria is a devastating disease of almost unfathomable impact, which according to the World Health Organization caused an estimated 219 million clinical cases and 435,000 deaths in 2017. Malaria directly reduces the Gross Domestic Product of African countries by at least 1% annually.

"Our goal is licensure and deployment of a vaccine to prevent malaria. We are excited to take our next step with the Government of Equatorial Guinea, Marathon Oil, Noble Energy and AMPCO on the pathway to PfSPZ Vaccine licensure and then malaria elimination on Bioko Island. This unique partnership continues to show the EG Government's commitment to being the first African government to invest significant funds in development of a malaria vaccine," said Stephen L. Hoffman, CEO of Sanaria.

The Republic of Equatorial Guinea, through the Ministries of Mines and Hydrocarbons, and Health and Social Welfare, and its

oil and gas sector partners will provide \$22M USD to support vaccine development and malaria control efforts within BIMEP for 2019, and the Government of EG, the major financial contributor in this initiative, will further provide \$4.5M over the next 3 years to directly support Sanaria's vaccine development efforts. These funds are in addition to the already-expended \$48M for the Equatoguinean Malaria Vaccine Initiative.

"The EG Government has recognized the potential of Sanaria's PfSPZ vaccines to be critical in elimination of malaria from our country and the rest of Africa," said the Minister of Mines and Hydrocarbons, His Excellency Gabriel Mbaga Obiang Lima. "With this in mind, we have committed our resources to accelerate development of Sanaria® PfSPZ Vaccine to licensure for future use on Bioko Island, and then our mainland and the rest of Africa."

Following three previous clinical trials, the next step is a Phase 3 clinical trial in Malabo, EG, which will provide data to support submission to US and European regulatory agencies for licensure of PfSPZ Vaccine. BIMEP is also supported by the Ifakara Health Institute (IHI) (Tanzania) and the Swiss Tropical and Public Health Institute.

Dr. Salim Abdulla, former IHI Director, recognized that "although other African governments have strong malaria control programs, none have made the financial commitment to malaria vaccine development made by the EG Government. This program has also supported the human and infrastructure capacity building critical for the Phase 3 clinical and malaria elimination programs."

The Vice Minister of Health and Social Welfare, Mitoha Ondo'o Ayekaba further stressed that, "this program also makes important contributions toward modernizing the healthcare system in the country, providing much needed training and state-of-the-art facilities on top of a unique vaccine development program."